In April of 2020 I wrote a piece on COVID therapeutics. It was speculative. Now in NEJM they assert that my speculation is correct. They note:
Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo.
NEJM present the data as:
The results are dramatic. My approach was to follow Galen, the physician to Marcus Aurelius. Two thousand years of medical practice based upon logic. Nice being right.
Posts
